Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Next Previous
Trial Profile

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Cannabidivarin (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Mar 2018 Planned initiation date changed from 1 Oct 2017 to 1 May 2018.
    • 05 Dec 2016 According to a GW Pharmaceuticals media release, the company expects to initiate this trial in the third quarter of 2017.
    • 31 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top